Biotech Values

[DewDiligence]

Sanofi Reports 1Q09 Annualized Lovenox Sales of $4.0B

[The sales figures below are in Euros, Sanofi’s reporting currency, but the growth rates are in local currencies unless otherwise specified. (Tallying growth in local currencies is a way to track the change in volume and price irrespective of exchange rates.) The sales figures below are annualized, i.e. they are 4x the 1Q09 numbers.]


Worldwide Lovenox sales in 1Q09 rose 1% year-over-year in local currencies (+6% in Euros) to an annualized rate of €3.05B, which is $4.0B at the current exchange rate. (Relative to 4Q08, worldwide Lovenox sales in 1Q09 increased 2% in Euros.)

In the US, where MNTA and partner NVS have filed an application to sell generic Lovenox, Sanofi’s annualized 1Q09 sales were €1.87B, which is $2.5B at the current exchange rate.

The breakdown of 1Q09 sales by geography is as follows:

US: €1.87B (61% of total), -1% YoY in lc
EU: €868M (28% of total), +5% YoY in lc
RoW: €308M (10% of total), +5% YoY in lc
===
Total: €3.05B, +1% YoY in lc

http://en.sanofi-aventis.com/binaries/20090429_q12009_en_tcm28-24993.pdf